Gentian Diagnostics ASA (DE:6FK) has released an update.
Gentian Diagnostics ASA is set to unveil a groundbreaking NT-proBNP assay at the ADLM 2024 clinical meeting that promises to enhance heart failure diagnostics by accurately measuring NT-proBNP levels without the interference of glycosylation. The new assay is compatible with high-throughput clinical chemistry platforms, offering improved cost and workflow efficiency while avoiding the common issue of underestimation caused by glycosylation in current assays. This innovation could significantly benefit patient management in heart failure cases by providing more reliable data.
For further insights into DE:6FK stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com